Difference between revisions of "Team:Vilnius-Lithuania/Design"

Line 156: Line 156:
 
         <h1>Background</h1>
 
         <h1>Background</h1>
 
       <p>
 
       <p>
           <p></p>
+
            
 
       </p>
 
       </p>
 
             <p>scFv consists of a minimal functional antigen-binding domain of an antibody (~30 kDa) (Fig. 1) , in which the heavy variable chain (VH) and light variable chain (VL) are connected by Ser and Gly rich flexible linker. [1] In most cases scFv is expressed in bacteria, where it is produced in cytoplasm, a reducing environment, in which disulfide bonds are not able to form and protein is quickly degraded or aggregated. Although poor solubility and affinity limit scFvs’ applications, their stability can be improved by merging with other proteins. [2] When expressed in cell free system, scFv should form disulfide bonds with the help of additional molecules. Merging to a membrane protein would provide additional stability and would display scFv on liposome membrane, where its activity could be detected. These improved qualities make ScFv recombinant proteins a perfect tool to evaluate, if SynDrop system acts in an anticipated manner. Of all possible scFvs we decided to use scFv-anti vaginolysin, which binds and neutralizes toxin vaginolysin (VLY). Its main advantage is rapid (< 1 h) and cheap detection of activity by inhibition of erythrocyte lysis (Fig. 2). Looking into future applications, scFvs are also attractive targets of molecular evolution, because one round of  evolution would last less than one day thus generating a and wide range of different scFv mutants. Those displaying the highest affinity for antigens could be selected and used as drugs or drug carriers. </p>
 
             <p>scFv consists of a minimal functional antigen-binding domain of an antibody (~30 kDa) (Fig. 1) , in which the heavy variable chain (VH) and light variable chain (VL) are connected by Ser and Gly rich flexible linker. [1] In most cases scFv is expressed in bacteria, where it is produced in cytoplasm, a reducing environment, in which disulfide bonds are not able to form and protein is quickly degraded or aggregated. Although poor solubility and affinity limit scFvs’ applications, their stability can be improved by merging with other proteins. [2] When expressed in cell free system, scFv should form disulfide bonds with the help of additional molecules. Merging to a membrane protein would provide additional stability and would display scFv on liposome membrane, where its activity could be detected. These improved qualities make ScFv recombinant proteins a perfect tool to evaluate, if SynDrop system acts in an anticipated manner. Of all possible scFvs we decided to use scFv-anti vaginolysin, which binds and neutralizes toxin vaginolysin (VLY). Its main advantage is rapid (< 1 h) and cheap detection of activity by inhibition of erythrocyte lysis (Fig. 2). Looking into future applications, scFvs are also attractive targets of molecular evolution, because one round of  evolution would last less than one day thus generating a and wide range of different scFv mutants. Those displaying the highest affinity for antigens could be selected and used as drugs or drug carriers. </p>
Line 170: Line 170:
  
 
         <h1>Results</h1>
 
         <h1>Results</h1>
 
+
<p></p>
         scFv constructs were created BBa_K2622006"Kristina" and checked by colony PCR and DNA sequencing (link to Simas construct protocol"Kristina"). scFv synthesis was performed in a cell free system. Validation of protein expression was done by running a sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), see (Fig. 3)
+
         <p>scFv constructs were created BBa_K2622006"Kristina" and checked by colony PCR and DNA sequencing (link to Simas construct protocol"Kristina"). scFv synthesis was performed in a cell free system. Validation of protein expression was done by running a sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE), see (Fig. 3)</p>
 
        
 
        
 
         <p>Fig. 3</p>
 
         <p>Fig. 3</p>
Line 191: Line 191:
 
       <h1>Conclusions</h1>
 
       <h1>Conclusions</h1>
 
       <p>
 
       <p>
          <p></p>
 
 
       </p>
 
       </p>
 
       <p>We successfully expressed scFv_antiVLY antibody and MstX-scFv_antiVLY construct in E.coli cells as well as in a cell free system. We demonstrated that our scFv anti-vaginolysin can bind to its target antigen vaginolysin and inhibit erythrocyte-lysis reaction. Based in scFv general properties in IVTT activity, we conclude that scFvs are an elegant addition to SynDrop liposome display system.</p>
 
       <p>We successfully expressed scFv_antiVLY antibody and MstX-scFv_antiVLY construct in E.coli cells as well as in a cell free system. We demonstrated that our scFv anti-vaginolysin can bind to its target antigen vaginolysin and inhibit erythrocyte-lysis reaction. Based in scFv general properties in IVTT activity, we conclude that scFvs are an elegant addition to SynDrop liposome display system.</p>
Line 203: Line 202:
 
       <p>
 
       <p>
 
         <ol>
 
         <ol>
         <li><p>
+
         <li>Monnier, P., Vigouroux, R. & Tassew, N. In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments. Antibodies 2, 193-208 (2013).</li>
            <ol>
+
            <li>Monnier, P., Vigouroux, R. & Tassew, N. In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments. Antibodies 2, 193-208 (2013).</li>
+
 
         <li>Wang, R. et al. Engineering production of functional scFv antibody in E. coli by co-expressing the molecule chaperone Skp. Frontiers in Cellular and Infection Microbiology 3, (2013).</li>   
 
         <li>Wang, R. et al. Engineering production of functional scFv antibody in E. coli by co-expressing the molecule chaperone Skp. Frontiers in Cellular and Infection Microbiology 3, (2013).</li>   
 
         <li>Ahmad, Z. et al. scFv Antibody: Principles and Clinical Application. Clinical and Developmental Immunology 2012, 1-15 (2012).</li>
 
         <li>Ahmad, Z. et al. scFv Antibody: Principles and Clinical Application. Clinical and Developmental Immunology 2012, 1-15 (2012).</li>
 
         <li>Vorauer-Uhl, K., Wagner, A., Borth, N. & Katinger, H. Determination of liposome size distribution by flow cytometry. Cytometry 39, 166 (2000).</li>
 
         <li>Vorauer-Uhl, K., Wagner, A., Borth, N. & Katinger, H. Determination of liposome size distribution by flow cytometry. Cytometry 39, 166 (2000).</li>
        </ol>
 
            </p></li>
 
 
         </ol>
 
         </ol>
 
         </p>
 
         </p>
 +
     
 
         </div>
 
         </div>
 
     </section>
 
     </section>

Revision as of 20:09, 17 October 2018

Design and Results

RNA Thermoswitches

Cell-free, synthetic biology systems open new horizons in engineering biomolecular systems which feature complex, cell-like behaviors in the absence of living entities. Having no superior genetic control, user-controllable mechanisms to regulate gene expression are necessary to successfully operate these systems. We have created a small collection of synthetic RNA thermometers that enable temperature-dependent translation of membrane proteins, work well in cells and display great potential to be transferred to any in vitro protein synthesis system.

invert